Antonio R. Lopez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antonio R. Lopez has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Gelareh Sadigh
University of California Irvine School of Medicine
2 shared publications Aiyah Jandali
1 shared publicationAnand Narayan
1 shared publicationAngela Whittington
1 shared publicationAntonio Escamilla Guevera
Department of Radiology, Denver Health , Denver, CO
1 shared publication- Antonio Reyes PorrasPerez
Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, 80045, CO, USA; Department of Pediatric Plastic & Reconstructive Surgery, Children's Hospital Colorado, Aurora, 80045, CO, USA; Department of Neurological Surgery, The University of Chicago, Chicago, 60637, IL, USA
1 shared publication
Latest Publications
- 30 July 2026
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23 (10) , 1931-1935
Patient Preferences Regarding Immediate Versus Delayed Release of Breast Biopsy Results in a Safety-Net Health System
- 30 July 2026
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23 (10) , 1931-1935
Patient Preferences Regarding Immediate Versus Delayed Release of Breast Biopsy Results in a Safety-Net Health System
- 21 July 2026
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 8 (5) , 530-539
Evaluating Allostatic Load as a Framework for Breast Cancer Risk Assessment Across Sociodemographic Groups: Insights from a Safety-Net Population
Objective: Allostatic load (AL) is an emerging framework quantifying physiological dysregulation from cumulative exposure to stressors over an individual’s life. We evaluated the relationship between AL and malignant breast biopsy results in women across sociodemographic subgroups. Methods: Women 18 years and older who underwent at least one image-guided breast biopsy at a safety-net hospital between April 2016 and December 2023 were identified. Consistent with prior studies, AL was defined as a score based on eight values: resting pulse rate, systolic blood pressure, diastolic blood pressure, body-mass index, serum albumin, creatinine, estimated glomerular filtration rate, and white blood cell count. Multivariable logistic regression models were used to assess the association between AL and malignant breast biopsy results among different sociodemographic groups. Effect modification by racial/ethnic category was then examined using stratified models. Results: 668 participants had data available for all eight biomarkers. Most participants were Hispanic (n = 376, 54.5%), reported English as their primary language (n = 423, 63.3%), and had Medicaid for insurance (n = 300, 44.9%). In stratified analyses, the association between AL and malignant breast biopsy result was significant in White, non-Hispanic patients. In White, non-Hispanic patients, after adjusting for age, every one-unit increase in AL was associated with a 46% increased likelihood of malignant breast biopsy result (OR 1.46, P = 0.03). Conclusion: AL was associated with malignant breast biopsy results in specific sociodemographic subgroups, potentially representing a modifiable risk factor for breast cancer prevention. Further research with large, diverse populations is required to evaluate additional factors impacting breast cancer outcomes across sociodemographic groups.
- 21 July 2026
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 8 (5) , 530-539
Evaluating Allostatic Load as a Framework for Breast Cancer Risk Assessment Across Sociodemographic Groups: Insights from a Safety-Net Population
Objective: Allostatic load (AL) is an emerging framework quantifying physiological dysregulation from cumulative exposure to stressors over an individual’s life. We evaluated the relationship between AL and malignant breast biopsy results in women across sociodemographic subgroups. Methods: Women 18 years and older who underwent at least one image-guided breast biopsy at a safety-net hospital between April 2016 and December 2023 were identified. Consistent with prior studies, AL was defined as a score based on eight values: resting pulse rate, systolic blood pressure, diastolic blood pressure, body-mass index, serum albumin, creatinine, estimated glomerular filtration rate, and white blood cell count. Multivariable logistic regression models were used to assess the association between AL and malignant breast biopsy results among different sociodemographic groups. Effect modification by racial/ethnic category was then examined using stratified models. Results: 668 participants had data available for all eight biomarkers. Most participants were Hispanic (n = 376, 54.5%), reported English as their primary language (n = 423, 63.3%), and had Medicaid for insurance (n = 300, 44.9%). In stratified analyses, the association between AL and malignant breast biopsy result was significant in White, non-Hispanic patients. In White, non-Hispanic patients, after adjusting for age, every one-unit increase in AL was associated with a 46% increased likelihood of malignant breast biopsy result (OR 1.46, P = 0.03). Conclusion: AL was associated with malignant breast biopsy results in specific sociodemographic subgroups, potentially representing a modifiable risk factor for breast cancer prevention. Further research with large, diverse populations is required to evaluate additional factors impacting breast cancer outcomes across sociodemographic groups.
- 1 January 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 310 (1) , e231469
Assessing the Relationship between Radiology Department Research Funding and Institutional Community Inclusion and Investment
Background Health care access disparities and lack of inclusion in clinical research have been well documented for marginalized populations. However, few studies exist examining the research funding of institutions that serve historically underserved groups. Purpose To assess the relationship between research funding awarded to radiology departments by the National Institutes of Health (NIH) and Lown Institute Hospitals Index rankings for inclusivity and community benefit. Materials and Methods This retrospective study included radiology departments awarded funding from the NIH between 2017 and 2021. The 2021 Lown Institute Hospitals Index rankings for inclusivity and community benefit were examined. The inclusivity metric measures how similar a hospital's patient population is to the surrounding community in terms of income, race and ethnicity, and education level. The community benefit metric measures charity care spending, Medicaid as a proportion of patient revenue, and other community benefit spending. Linear regression and Pearson correlation coefficients (r values) were used to evaluate the relationship between aggregate NIH radiology department research funding and measures of inclusivity and community benefit. Results Seventy-five radiology departments that received NIH funding ranging from $195 000 to $216 879 079 were included. A negative correlation was observed between the amount of radiology department research funding received and institutional rankings for serving patients from racial and/or ethnic minorities (r = -0.34; P < .001), patients with low income (r = -0.44; P < .001), and patients with lower levels of education (r = -0.46; P < .001). No correlation was observed between the amount of radiology department research funding and institutional rankings for charity care spending (r = -0.19; P = .06), community investment (r = -0.04; P = .68), and Medicaid as a proportion of patient revenue (r = -0.10; P = .22). Conclusion Radiology departments that received more NIH research funding were less likely to serve patients from racial and/or ethnic minorities and patients who had low income or lower levels of education. © RSNA, 2024 See also the editorial by Mehta and Rosen in this issue.
- 1 January 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 310 (1) , e231469
Assessing the Relationship between Radiology Department Research Funding and Institutional Community Inclusion and Investment
Background Health care access disparities and lack of inclusion in clinical research have been well documented for marginalized populations. However, few studies exist examining the research funding of institutions that serve historically underserved groups. Purpose To assess the relationship between research funding awarded to radiology departments by the National Institutes of Health (NIH) and Lown Institute Hospitals Index rankings for inclusivity and community benefit. Materials and Methods This retrospective study included radiology departments awarded funding from the NIH between 2017 and 2021. The 2021 Lown Institute Hospitals Index rankings for inclusivity and community benefit were examined. The inclusivity metric measures how similar a hospital's patient population is to the surrounding community in terms of income, race and ethnicity, and education level. The community benefit metric measures charity care spending, Medicaid as a proportion of patient revenue, and other community benefit spending. Linear regression and Pearson correlation coefficients (r values) were used to evaluate the relationship between aggregate NIH radiology department research funding and measures of inclusivity and community benefit. Results Seventy-five radiology departments that received NIH funding ranging from $195 000 to $216 879 079 were included. A negative correlation was observed between the amount of radiology department research funding received and institutional rankings for serving patients from racial and/or ethnic minorities (r = -0.34; P < .001), patients with low income (r = -0.44; P < .001), and patients with lower levels of education (r = -0.46; P < .001). No correlation was observed between the amount of radiology department research funding and institutional rankings for charity care spending (r = -0.19; P = .06), community investment (r = -0.04; P = .68), and Medicaid as a proportion of patient revenue (r = -0.10; P = .22). Conclusion Radiology departments that received more NIH research funding were less likely to serve patients from racial and/or ethnic minorities and patients who had low income or lower levels of education. © RSNA, 2024 See also the editorial by Mehta and Rosen in this issue.
- Open Access
Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers
The mitogen-activated protein kinase (MAPK) pathway, consisting of the Ras-Raf-MEK-ERK signaling cascade, regulates genes that control cellular development, differentiation, proliferation, and apoptosis. Within the cascade, multiple isoforms of Ras and Raf each display differences in functionality, efficiency, and, critically, oncogenic potential. According to the NCI, over 30% of all human cancers are driven by Ras genes. This dysfunctional signaling is implicated in a wide variety of leukemias and solid tumors, both with and without viral etiology. Due to the strong evidence of Ras-Raf involvement in tumorigenesis, many have attempted to target the cascade to treat these malignancies. Decades of unsuccessful experimentation had deemed Ras undruggable, but recently, the approval of Sotorasib as the first ever KRas inhibitor represents a monumental breakthrough. This advancement is not without novel challenges. As a G12C mutant-specific drug, it also represents the issue of drug target specificity within Ras pathway; not only do many drugs only affect single mutational profiles, with few pan-inhibitor exceptions, tumor genetic heterogeneity may give rise to drug-resistant profiles. Furthermore, significant challenges in targeting downstream Raf, especially the BRaf isoform, lie in the paradoxical activation of wild-type BRaf by BRaf mutant inhibitors. This literature review will delineate the mechanisms of Ras signaling in the MAPK pathway and its possible oncogenic mutations, illustrate how specific mutations affect the pathogenesis of specific cancers, and compare available and in-development treatments targeting the Ras pathway.
Open AccessProgress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers
The mitogen-activated protein kinase (MAPK) pathway, consisting of the Ras-Raf-MEK-ERK signaling cascade, regulates genes that control cellular development, differentiation, proliferation, and apoptosis. Within the cascade, multiple isoforms of Ras and Raf each display differences in functionality, efficiency, and, critically, oncogenic potential. According to the NCI, over 30% of all human cancers are driven by Ras genes. This dysfunctional signaling is implicated in a wide variety of leukemias and solid tumors, both with and without viral etiology. Due to the strong evidence of Ras-Raf involvement in tumorigenesis, many have attempted to target the cascade to treat these malignancies. Decades of unsuccessful experimentation had deemed Ras undruggable, but recently, the approval of Sotorasib as the first ever KRas inhibitor represents a monumental breakthrough. This advancement is not without novel challenges. As a G12C mutant-specific drug, it also represents the issue of drug target specificity within Ras pathway; not only do many drugs only affect single mutational profiles, with few pan-inhibitor exceptions, tumor genetic heterogeneity may give rise to drug-resistant profiles. Furthermore, significant challenges in targeting downstream Raf, especially the BRaf isoform, lie in the paradoxical activation of wild-type BRaf by BRaf mutant inhibitors. This literature review will delineate the mechanisms of Ras signaling in the MAPK pathway and its possible oncogenic mutations, illustrate how specific mutations affect the pathogenesis of specific cancers, and compare available and in-development treatments targeting the Ras pathway.